A publication describes TREM2-activating compounds proposed for ALS treatment
Original source
Novel Compounds as TREM2 Agonists for Treating Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Nasu-Hakola Disease, and Stroke. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Commentary
A publication describes new compounds identified as TREM2 agonists and proposes their use in treating amyotrophic lateral sclerosis (ALS), alongside several other diseases. It also describes related pharmaceutical compositions and preparation processes.【S1】
Why this matters
This may be relevant to researchers investigating TREM2-targeting drug candidates. The source does not report testing in people or show that the compounds improve ALS, so it does not change treatment for people living with ALS.【S1】
Limitations and context
The source is an editorial, not a report of a clinical trial or demonstrated treatment benefit. It provides no results on safety, effectiveness, dosing, or testing in people with ALS. Further research would be needed to establish whether these compounds work and are safe.